{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:19Z","timestamp":1792788619070,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Mayo Clinic Breast Cancer Specialized Program of Research Excellence Grant","award":["P50CA 116201"],"award-info":[{"award-number":["P50CA 116201"]}],"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20151-z","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:24:02Z","timestamp":1784813042000},"page":"9803-9814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time Interval Between Neoadjuvant Chemotherapy Completion and Mastectomy is Not Associated with 30-Day Complication Rate"],"prefix":"10.1245","volume":"33","author":[{"given":"Lilia G.","family":"Lunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya L.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Degnim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milissa M.","family":"Klebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Marden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3228","authenticated-orcid":false,"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"7","key":"20151_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med."},{"issue":"22","key":"20151_CR2","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med."},{"key":"20151_CR3","doi-asserted-by":"publisher","unstructured":"Schmid P, Cortes J, Pusztai L, KEYNOTE-522 Investigators et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810-21. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","DOI":"10.1056\/NEJMoa1910549"},{"issue":"4","key":"20151_CR4","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1245\/s10434-025-19065-z","volume":"33","author":"CN Day","year":"2026","unstructured":"Day CN, Habermann EB, Boughey JC. Evolution of breast cancer treatment 2010\u20132023. Ann Surg Oncol. 2026;33(4):3244\u201353.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"20151_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485\u2013505.","journal-title":"J Clin Oncol."},{"key":"20151_CR6","unstructured":"National Comprehensive Cancer Network. Breast cancer. Version current as of February 27, 2026. Accessed 23 Apr 2026. https:\/\/www.nccn.org"},{"key":"20151_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104454","volume":"81","author":"D Wang","year":"2025","unstructured":"Wang D, Sun X, Sun W, et al. Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: a comprehensive systematic review and meta-analysis. Breast. 2025;81:104454.","journal-title":"Breast."},{"issue":"11","key":"20151_CR8","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1245\/s10434-025-17933-2","volume":"32","author":"J Van Hassel","year":"2025","unstructured":"Van Hassel J, Dimitroff K, Yau C, et al. Impact of time to surgery post neoadjuvant chemotherapy on breast cancer outcomes: A retrospective study of patients enrolled in the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(11):8113-126. https:\/\/doi.org\/10.1245\/s10434-025-17933-2.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"20151_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ejso.2021.01.025","volume":"47","author":"C Cullinane","year":"2021","unstructured":"Cullinane C, Shrestha A, Al Maksoud A, et al. Optimal timing of surgery following breast cancer neoadjuvant chemotherapy: A systematic review and meta-analysis. Eur J Surg Oncol. 2021;47(7):1507\u201313.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"20151_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.amjsurg.2020.02.061","volume":"219","author":"TL Sutton","year":"2020","unstructured":"Sutton TL, Johnson N, Schlitt A, Gardiner SK, Garreau JR. Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates. Am J Surg. 2020;219(5):741\u20135.","journal-title":"Am J Surg."},{"issue":"3","key":"20151_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10549-020-05894-x","volume":"184","author":"V Lai","year":"2020","unstructured":"Lai V, Hajjaj O, Le D, et al. Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from neoadjuvant chemotherapy for surgery. Breast Cancer Res Treat. 2020;184(3):755\u201362.","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"20151_CR12","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/wjs.12258","volume":"48","author":"S Bek","year":"2024","unstructured":"Bek S, Sultana R, Du SX, Tan QT. Time to surgery after completion of neoadjuvant chemotherapy does not negatively impact recurrence and survival outcomes in breast cancer patients. World J Surg. 2024;48(8):1921\u20138.","journal-title":"World J Surg."},{"issue":"11","key":"20151_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364\u201382.","journal-title":"Arch Pathol Lab Med."},{"key":"20151_CR14","volume-title":"AJCC Cancer Staging Manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, et al editors. AJCC Cancer Staging Manual. 8th edn. Cham: Springer; 2017.","edition":"8"},{"issue":"28","key":"20151_CR15","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, et al. Measurements of residual cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414\u201322. https:\/\/doi.org\/10.1200\/JCO.2007.10.6823.","journal-title":"J Clin Oncol."},{"issue":"12","key":"20151_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373\u20139.","journal-title":"J Clin Epidemiol."},{"issue":"7\u20138","key":"20151_CR17","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/sim.3794","volume":"29","author":"G Heinze","year":"2010","unstructured":"Heinze G, Puhr R. Bias-reduced and separation-proof conditional logistic regression with small or sparse data sets. Stat Med. 2010;29(7\u20138):770\u20137.","journal-title":"Stat Med."},{"issue":"9","key":"20151_CR18","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1245\/s10434-019-07418-4","volume":"26","author":"AJ Bartholomew","year":"2019","unstructured":"Bartholomew AJ, Dervishaj OA, Sosin M, et al. Neoadjuvant chemotherapy and nipple-sparing mastectomy: Timing and postoperative complications. Ann Surg Oncol. 2019;26(9):2768\u201372.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"20151_CR19","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1245\/s10434-019-07408-6","volume":"26","author":"K Adamson","year":"2019","unstructured":"Adamson K, Chavez-MacGregor M, Caudle A, et al. Neoadjuvant chemotherapy does not increase complications in oncoplastic breast-conserving surgery. Ann Surg Oncol. 2019;26(9):2730-37.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20151_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejso.2021.09.007","volume":"48","author":"T Lorentzen","year":"2022","unstructured":"Lorentzen T, Heidemann LN, M\u00f6ller S, Bille C. Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(1):44\u201352.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"20151_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/SLA.0000000000001804","volume":"265","author":"ME Bowen","year":"2017","unstructured":"Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW. Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherpy: A propensity-matched analysis.\u00a0Ann Surg. 2017;265(3):448\u201356.","journal-title":"Ann Surg."},{"issue":"8","key":"20151_CR22","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1245\/s10434-024-15359-w","volume":"31","author":"SP Myers","year":"2024","unstructured":"Myers SP, Sevilimedu V, Jones VM, et al. Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer. Ann Surg Oncol. 2024;31(8):5180\u20138.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20151-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:18:48Z","timestamp":1790867928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20151-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20151"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20151-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Judy Boughey receives research funding paid to institution from Eli Lilly, SimBioSys, and Quantum Leap Healthcare. Dr. Boughey is on the DSMC for Cairn Surgical.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}